enanthate testosterone

For the short-term treatment of pain of various origins moderate intensity:

  • diseases of the musculoskeletal system (rheumatoid arthritis, psoriatic, juvenile chronic arthritis, enanthate testosterone¬†ankylosing spondylitis, gouty arthritis, rheumatic soft tissue osteroartroz peripheral joints and spine, including radicular syndrome, tendonitis, bursitis);
  • neuralgia, myalgia, sciatica, post-traumatic pain, accompanied by inflammation, postoperative pain, headache, migraine, tuberculosis, adnexitis, proctitis.
  • Feverish syndrome.

Hypersensitivity (incl to others. NSAIDs), erosive and ulcerative lesions of the gastrointestinal tract, “Aspirin” triad, violations of hematopoiesis, hemostasis disorders (including hemophilia), pregnancy, children’s age (up to 18 s), lactation.

Anemia, asthma, congestive heart failure, arterial hypertension, edema syndrome, liver or kidney failure, alcoholism, inflammatory bowel disease, erosive and ulcerative diseases of the gastrointestinal tract without exacerbation, diabetes, conditions after major surgery, induced porphyria , advanced age, diverticular disease, systemic connective tissue diseases.

Dosage and administration
injected deep intramuscularly. The single dose for adults – 75 mg (1 ampoule). If necessary, you may re-introduction, but not earlier than after 12 hours.
Duration of no more than 2 days, if necessary further switching to oral or rectal .

Side effects

Gastrointestinal tract:
Usually 1% – abdominal pain, feeling of bloating, diarrhea, nausea, constipation, flatulence, increased levels of “liver” enzymes, peptic ulcer with possible complications (bleeding, perforation), gastrointestinal bleeding,
Less 1% – vomiting, jaundice, melena, blood in the stool, esophageal damage, aphthous stomatitis, dry mouth and mucous membranes, hepatitis (possibly fulminant), liver necrosis, cirrhosis, hepatorenal syndrome, appetite change, pancreatitis, holetsistopankreatit, colitis.

Nervous system:
Usually 1% – headache, dizziness.
Less 1% – insomnia, drowsiness, depression, irritability, aseptic meningitis (usually in patients with systemic lupus erythematosus and other connective tissue diseases), cramps, weakness, disorientation, nightmares , a sense of fear.

Usually 1% – tinnitus.
Less 1% – blurred vision, diplopia, disturbance of taste, reversible or irreversible hearing loss, scotoma.

Usually 1% – pruritus, skin rash.
Less 1% – alopecia, urticaria, eczema, chronic dermatitis, erythema multiforme, incl Stevens-Johnson syndrome, enanthate testosterone¬†toxic epidermal necrolysis (Lyell’s syndrome), increased photosensitivity, melkotochechnye hemorrhage.

Usually 1% – fluid retention.
Less 1% – nephrotic syndrome, proteinuria, oliguria, hematuria, interstitial nephritis, papillary necrosis, acute renal failure, azotemia.

Organs of hematopoiesis and immune system:
Less 1% – anemia (including haemolytic and aplastic anemia), leukopenia, thrombocytopenia, eosinophilia, agranulocytosis, thrombocytopenic purpura, worsening of infectious processes (development of necrotizing fasciitis, pneumonia).

Respiratory system:
Less 1% – cough, bronchospasm, laryngeal edema, pneumonitis.

Cardiovascular system:
Less 1% – high blood pressure, congestive heart failure, beats, chest pain.

Allergic reactions:
Less 1% – an anaphylactic reaction, anaphylactic shock (usually develops rapidly), swelling of the lips and tongue, allergic vasculitis.

Local reactions when administered intramuscularly:
Burning, infiltration, aseptic necrosis, necrosis of adipose tissue.

Overdose Symptoms: vomiting, dizziness, headache, shortness of breath, dizziness, children – myoclonic seizures, nausea, abdominal pain, bleeding, liver and kidney function. Treatment: . Symptomatic therapy, forced diuresis Hemodialysis is ineffective.


Interaction with other drugs
increases the plasma concentration of digoxin, methotrexate, lithium and cyclosporine drugs.
Reduces the effect of diuretics, potassium-sparing diuretics in the background increases the risk of hyperkalemia; amid anticoagulants, thrombolytic agents (alteplase, streptokinase, urokinase.) – bleeding risk (usually from the gastrointestinal tract)
reduces the effects of antihypertensive and hypnotics.
, increases the likelihood of side effects of other NSAIDs and glucocorticoid means (bleeding in the gastrointestinal tract) , the toxicity of methotrexate and cyclosporine nephrotoxicity.
Aspirin reduces the concentration of in the blood.
Simultaneous use of paracetamol increases the risk of nephrotoxic effects of .
reduces the effect of hypoglycemic agents.
Tsefamandol, ceftazidime, tsefotetan, enanthate testosterone valproic acid and plikamitsin increase the incidence of gipoprotrombinemii.
cyclosporine and preparations of gold increase impact synthesis of prostaglandins in the kidneys, which improves nephrotoxicity.
Co-administration with ethanol, colchicine, corticotropin and preparations Hypericum increased risk of hemorrhages in the gastrointestinal tract.
increases the effects of drugs that cause photosensitization.
drugs that block tubular secretion, increase the concentration of in plasma, thereby increasing its toxicity. kob steroider